Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's,Published Study on Culture Blood-Forming Stem Cells from Human Fat,Tissue as Supporting Near Term Benefits of Banking Adipose (Fat),Derived Stem Cells ( tissue. Currently Bio-Matrix is work...)

HOME >> MEDICINE >> TECHNOLOGY

Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's,Published Study on Culture Blood-Forming Stem Cells from Human Fat,Tissue as Supporting Near Term Benefits of Banking Adipose (Fat),Derived Stem Cells

tissue.

Currently, Bio-Matrix is working towards opening its 15,000 square foot Stem Cell Banking facility. The focus of this facility will be the banking of Adipose (Fat) derived stem cells.

Dr. Geoffrey O'Neill received his Ph.D. in Immunology from the University of Glasgow in 1973. In 1974, he undertook post-doctoral training under the guidance of Dr. Robert A. Good (who performed the first bone marrow transplantation in a patient with immunodeficiency) at Memorial Sloan-Kettering Cancer Center in New York. Dr. O'Neill's field of study at Sloan-Kettering was transplantation immunobiology.

Dr. O'Neill has over twenty five years' experience in his field, achieving recognition from his colleagues as the recipient of the Jean Julliard Prize for Outstanding Research from the International Society of Blood Transfusion and International Society of Hematology, presented in Budapest, Hungary. He also received the JM Foundation Award, New York, for innovative research.

About Bio-Matrix Scientific Group

Bio-Matrix Scientific Group Inc. (www.BMSNonline.com) is a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market. The company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation. Bio-Matrix' new 15,000 sq. ft. state-of-the-art facility, located in the heart of San Diego's biotechnology corridor, plans to open in September 2007. It will house Bio-Matrix' secure Cryogenic Stem Cell Bank, three research laboratories, aseptic cellular/tissue class 10,000/100 processing laboratory, hematology, microbiology and flow cytometry laboratories. The facility plans to cater to the growing stem cell research segment of the $75 billion biotechnology and medical
'"/>

Page: 1 2 3
Related medicine technology :

1. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
2. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
3. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
4. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
5. Vaxiion Researchers Discover Novel Vaccine Delivery System in Collaboration with San Diego State University
6. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
7. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
8. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:

(Date:12/2/2009)... ALTO, Calif., Dec. 2 Va...mber 25, 2009, Varian, Inc. filed with the U.S. Se... on Form 10-K for the fiscal year ended October 2,... the Company,s web site at www.varianinc.com, by c... on "10-K" in the table shown. Stockholders may r...

(Date:12/2/2009)... NEW YORK, Dec. 2 Reportlinker.com...ailable in its catalogue: ,, Pharmaceutical C..., http://www.reportlinker.com/p0164248/Pharmace...ds.html ,, Global pharma industry faces nume...ion in generic markets, rising cost of new product...

(Date:12/2/2009)... PARK, Ill., Dec. 2 Abbo...ing a vast array of microorganisms has been named ...st magazine. A panel of expert judges evaluated ...rmine the year,s top innovations, with the winners...online at www.the-scien t ist.com/top10innovat...

Breaking Medicine Technology:Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 2 Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 3 Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 4 Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 5 Abbott's Ibis Technology Named One of the Top Innovations for 2009 by The Scientist 2 AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 1 AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 2 AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 3 First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 1 First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 2 First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 3 Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter 5865 1 Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter 5865 2

[0] Varian, Inc. Announces Form 10-K Filing [0] Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends [0] Abbott's Ibis Technology Named One of the Top Innovations for 2009 by The Scientist

...ences, Inc. (Nasdaq: RDEA ) today announced that ...ty of the Company,s non-nucleoside reverse,transcr...st the,human-immunodeficiency virus (HIV), the kno...nt strains., The data was presented at the 15th A... Infections (CROI) in Boston., The data showed th...

...and lipid effects between REYATAZ/ritonavir and...CETON, N.J., Feb. 6 Bristol-Myers Squibb,Company ...TLE study, in which,300 mg of once-daily REYATAZ(R...vir (REYATAZ/r) showed similar antiviral efficacy ...mg (lopinavir/r) in previously untreated,adult HIV...

Other Medicine Technology:Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus 2 Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus 3 CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 2 CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 3 CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 4 CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 5 CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 6

Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients

(Date:12/2/2009)...c. 2 Reportlinker.com announces th...s catalogue: ,, Point of Care Diagnostics ,...Care-Diagnostics.html ,, Provides a complete r...nostics industry ,, Includes market forecasts t... ,, Covers federal regulation of POC testing ,...

(Date:12/2/2009)...Dec. 2 The Washington Post reporte...ording to Coremetrics, a marketing optimization co...onday compared to Cyber Monday 2008. ,, Contras...pas who reported today "Cyber Monday website traff...9%" - said Tiffany Amorosino, COO of Bella Sante. ...

(Date:12/2/2009)...ave metabolic syndrome, study finds , , ...ne isn,t enough to keep overweight college footbal...condition that can lead to heart disease, a new st...Division I colleges and found that two-thirds were...e, a group of conditions that raise the risk for h...

(Date:12/2/2009)... 2 In the wake of the f...inated with a plastics chemical linked to birth de...tely to protect infants and mothers. ,, The Hou...ol A, or BPA, in food and beverage containers. The... Rep. Edward Markey of Massachusetts, would protec...

(Date:12/2/2009).... 2 Independence Blue Cross (IBC) ...ith Lincoln Financial Group. IBC will be the prima...10,000 Lincoln Financial Group employees, retirees...oln plan offerings will include the PPO option and...I speak for all of us at Independence Blue Cross w...

[0] Reportlinker Adds Point of Care Diagnostics [0] The Washington Post Reported That Cyber Monday Website Traffic Rises 8%. Boston's Bella Sante Day Spas Cyber Monday Website Traffic Rises 76%.[0] Oversized College Football Players May Face Heart Risks [0] Pre-Polluted Babies: Congress Must Act to Protect Infants, Moms from Toxic Plastics Chemical BPA [0] Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group

...at the cox-2 inhibitor celecoxib, a common pain re...k of the most common cause of brain damage in pre...p blood vessels in a part of the brain that in pre...lastingly affected by cerebral palsy, mental retar...

...e risk of a type of kidney malignancy called renal...hers at Brigham and Women's Hospital in Boston fou...alcoholic beverage a day were about 30 percent les...nd other researchers reviewed data from 12 studies...

...s generally suffer in silence, cough up more money...th mixed results. And here comes the news tha...ring warranty on its workmanship, charging a flat ...nd the insurer another bill. Well the Geisin...

... a health authority in St. John's, Canada, has apo...tests that may have affected the care of hundreds...the Eastern Health Regional Authority agreed that ... that we didn't simply refer to it earlier,' Tille...

...of Cincinnati have developed a model that could im... helping physicians combine current clot-busting ...othermia. It is already known that lowerin...pproved stroke medication is an enzyme called tiss...

...s of the four sick public sector pharmaceutical an...overnments , the railways and the armed forces hav...hem profit making units. According to the ... Hindustan Organic Chemicals Limited have been rev...

Other Medicine News:Health News:Common Pain Killer may Reduce the Risk of Brain Damage in Premature Babies 2 Health News:Common Pain Killer may Reduce the Risk of Brain Damage in Premature Babies 3 Health News:US Hospital Group Offers Warranty on Surgeries 2 Health News:US Hospital Group Offers Warranty on Surgeries 3 Health News:Faulty Hormone Tests Compromised Healthcare Of Breast Cancer Patients 2 Health News:Researchers Develop Model That Aids in Treating Stroke Patients 2 Health News:Government Hospitals to the Rescue of Loss-making Pharma Companies 2

Common Pain Killer may Reduce the Risk of Brain Damage in Premature Babies Moderate Drinking may Lower Risk of Kidney Cancer US Hospital Group Offers Warranty on Surgeries Faulty Hormone Tests Compromised Healthcare Of Breast Cancer Patients Researchers Develop Model That Aids in Treating Stroke Patients Government Hospitals to the Rescue of Loss-making Pharma Companies

Olympus osYris AutoPPI™

IMAGETEAM™ 4600PDF

...tband ideal for positive patient identification an...closures provide a secure seal, with five colors p...for use with Zebra printers for peak performance. ... photos. Flexible and latex-free, waterproof, with...

DataMate Laser Label Sheets for Insert Wristbands

Medicine Products:

Olympus osYris AutoPPI™IMAGETEAM™ 4600PDF Z-Band QuickClip DataMate Laser Label Sheets for Insert Wristbands

( tissue. Currently Bio-Matrix is work...)Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's,Published Study on Culture Blood-Forming Stem Cells from Human Fat,Tissue as Supporting Near Term Benefits of Banking Adipose (Fat),Derived Stem Cells,Health